Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: A preliminary report of a phase I dose escalation trial from the carolina conformal therapy consortium

Oncologist

Volumn 6, Issue SUPPL. 1, 2001, Pages 20-24

  Socinski, M A ^a   Marks, L B ^b   Garst, J ^b   Sibley, G S ^b   Blackstock, W ^b   Turrisi, A ^b   Herndon, J ^b   Zhou, S ^b   Anscher, M ^b   Crawford, J ^b   Shafman, T ^b   Rosenman, J ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

AHCRT; Carboplatin; Paclitaxel; TRT; Vinorelbine

Indexed keywords

CARBOPLATIN; NAVELBINE; PACLITAXEL;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035126491     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_1-20     Document Type: Conference Paper

References (22)

1. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung
2. Long-term observations of the pattern of failure in patients with unresectable non-oat-cell carcinoma of the lung treated with definite radiotherapy
3. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 535 patients
4. A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: Results of a randomized equivalence study
5. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: A retrospective multivariate analysis
6. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: Unusual toxicity and promising early results
7. Induction therapy for NSCLC: A consensus report
8. Benefits of neoadjuvant chemotherapy in NSCLC
9. The role of induction (neoadjuvant) chemotherapy in Stage IIIA NSCLC
10. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small cell lung cancer without overt metastases
11. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists
12. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer
13. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced non-small cell lung cancer
14. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
15. Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small cell lung cancer patients
16. Induction chemotherapy (ICT cisplatin and vinorelbine) followed by a combination of daily irradiation and carboplatin (CBCDA) stage IIIB non-small cell lung cancer (NSCLC): Final analysis of a phase II trial
17. Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/ carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer
18. Combined-modality therapy for advanced non-small cell lung cancer: Paclitaxel and thoracic irradiation
19. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center study 94-001
20. Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC
21. Induction carboplatin/paclitaxel followed by concurrent carboplatin/ paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: A modified Phase I trial
22. LENT SOMA scales for all anatomic sites